Although pharma companies have traditionally enjoyed considerable success in Eastern European markets, healthcare systems in the region have become increasingly complex in recent years. Governments have begun launching healthcare reforms to reduce costs, and new legislation has started to shift decision-making responsibility for prescription drugs from physicians to pharmacies. Many new member states have replaced state-controlled healthcare systems with regulated social health insurance systems and several countries have also opened up their health insurance markets to competition from private insurers.
Eastern European Pharmaceutical Market Outlook to 2014 explores the healthcare systems and policy environments of eight Eastern European countries. For each country, this report provides an assessment of market structure, pricing/regulation and key brands, in addition to a detailed epidemiological analysis of major indications. The growth drivers of the region are identified and forecasts for major prescription drugs and markets are provided for the period 2009-14. The competitive landscape of the Eastern European market is also evaluated, with the region’s six leading companies being assessed based upon their marketed product portfolios, R&D pipelines and current competitive positions within each country.
Key Findings
The Eastern European pharma market is forecast to grow at a CAGR of 10.2% to reach a value of $41.4bn in 2014. The cardiovascular market is expected to register the highest sales
($7.8bn
) in 2014, followed by alimentary canal & metabolic disorders
($6bn
).
Romania recorded the highest growth in pharma sales over the 2006–07 period
(44.6%
), followed by Slovakia
(37.1%
). Growth in these markets has been driven by increasing access to modern medicines, as regional branded generic manufacturers enter the market and take share from domestic suppliers.
Novartis led the Eastern European pharma market with $1.5bn sales in 2007, a 27.3% increase over 2006. The company has the unique advantage of marketing both generic and branded pharma products across a wide range of therapy areas.
Lovenox
(enoxaparin
) from Sanofi-Aventis was the leading treatment in the Eastern European pharma market in 2007, with sales of $152m. Other leading brands were dominated by low molecular weight fractionated heparin and ACE inhibitor drugs.
Use this report to
- Compare the healthcare markets of key Eastern European countries with this report’s macroeconomic analysis of infrastructure, per capita health expenditure and pharma sales growth vs. GDP growth across Russia, Ukraine, Poland, Romania, Czech Republic, Hungary, Slovakia and Slovenia.
- Understand how healthcare systems vary across Eastern European countries with this report’s examination of the pricing regulations, reimbursement policies and regulatory environments of each country.
- Identify which indications have the greatest potential to provide franchise growth with this report’s evaluation of major therapy/sub-therapy areas and leading brands, including forecast sales over the period 2009-2014.
- Measure the performances and prospects of leading companies in Eastern Europe with this report’s analysis of sales focus by drug class, currently marketed products and R&D pipeline portfolios for Novartis, GSK, Sanofi-Aventis, Servier, Roche and Zentiva.
Explore issues including
Cost effective measures to improve healthcare systems in Eastern Europe. Most of the new member states of Eastern Europe have replaced their state controlled healthcare pricing and reimbursement systems with regulated social health insurance systems similar to those in major EU countries. The Czech Republic and Slovakia have opened up their health insurance markets to competition from private insurers.
Benefits for generic drug makers in Eastern Europe. In contrast to most Western European generics markets, success in Eastern European countries is generated by building strong branded generics. As a result, niche players tend to succeed with their products. This is demonstrated by Krka, who led the 2007 market in Slovenia with their generic OTC gastrointestinal product Ultop.
Biosimilar acceptance to reduce drug expenditure. Cost containment is a key concern for all major Eastern European governments, as most of them are experiencing severe pressure to curb rising pharma expenditure. A key driver for the uptake of biosimilars will be governmental attitudes towards promoting them as an affordable alternative to originator medicines. Although success is initially expected from well established generic manufacturers with advanced development programs, several small to medium sized biopharmaceutical companies are expected to emerge in the longer-term.
Discover
- What will be the drivers of growth in Eastern European pharma markets during 2009-14?
- Which companies will become key players in the Eastern European market over the period 2009–14?
- Which products will be affected by generic competitors over 2009-13?
- Which pipeline products will be the growth drivers of the future?
- Which therapeutic categories have the highest market potential over 2009-14?
- What will the competitive landscape look like in cardiovascular, oncology, CNS and respiratory markets of Eastern Europe in 2014?
- How will the larger pharma markets of Russia, Ukraine and Poland perform in the future?
- How is the healthcare system structured in Russia, Poland, Ukraine, Hungary, Romania, Czech Republic, Slovakia and Slovenia?
Table of Contents207 pagesPublication Date : July 2009
)
